Study on the efficacy of compound porcine cerebroside and ganglioside injection in patients with ischemic stroke: A randomized, single-center, open-label, prospective study.

Compound porcine perebroside and ganglioside injection (CPCGI) was used to treat stroke. The study was initiated because of the high incidence of low-does CPCGI use in our area. However, no research has confirmed the effectiveness of CPCGI below the standard dose. Therefore, the aim of this study was to provide a reference for the clinical selection of different dose treatments. We collected ischemic stroke patients and divided them into three groups (low-dose group: Group A = 4 mL, Group B = 6 mL, standard-dose group: Group C = 10 mL). The modified Rankin Scale (mRS) scores, the National Institutes of Health Stroke Scale (NIHSS) scores, and the Barthel Index (BI) scores were performed before treatment and 14 days and 90 days post CPCGI treatment. For 90 days, the primary outcomes were calculated including the degree of disability, neurological recovery, and activities of daily living. All data were compared between pretherapy and posttreatment and among groups. NIHSS, mRS and BI scores improved on 14 and 90 days in each group. Group B and C improved than Group A on 14 and 90 days. The difference between groups B and C was not statistically significant. On 90 days, there were differences in the degree of disability, the recovery of neurological function, and the ability of daily living among groups. No drug-related adverse reactions occurred in the groups. Although 4 or 6 mL CPCGI had some neuroprotective effects, the standard dose of 10 mL CPCGI had the best effect on reducing the degree of disability and improving abilities of daily living.